This article may rely excessively on sources too closely associated with the subject , potentially preventing the article from being verifiable and neutral.(January 2014) |
The Access to Medicine Index is a ranking system published biennially since 2008 by the Access to Medicine Foundation, an international not-for-profit organisation based in Amsterdam, the Netherlands. It ranks 20 of the world's largest pharmaceutical companies according to their ability to make their pharmaceutical drugs more available, affordable and accessible in low- and middle-income countries. [1] The Index aims to stimulate companies to improve access in developing countries, to show the activities of their peers, [2] [3] and allow them, governments, investors, civil society, patient organisations and academia to understand how pharmaceutical companies can make further progress. The 2022 Access to Medicine Index was funded by the Dutch Ministry of Foreign Affairs, the UK Foreign, Commonwealth and Development Office, the Bill & Melinda Gates Foundation, Axa Investment Managers, and the Wellcome Trust. [4] [5]
The latest Access to Medicine Index, published in November 2022, ranked the 20 pharmaceutical companies as follows: [6] [5]
Company name (2022 score) | 2022 ranking | 2021 ranking | 2018 ranking | 2016 ranking |
---|---|---|---|---|
GSK plc (4.06) | 1 | 1 | 1 | 1 |
Johnson & Johnson (4.03) | 2 | 3 | 2 | 3 |
AstraZeneca plc. (3.93) | 3 | 7 | 3 | 2 |
Novartis AG (3.87) | 4 | 2 | 11 | 14 |
Merck KGaA (3.72) | 5 | 8 | 7 | 6 |
Pfizer Inc (3.62) | 6 | 4 | 5 | 15 |
Takeda Pharmaceutical Co. Ltd (3.51) | 7 | 6 | 9 | 7 |
Sanofi (3.47) | 8 | 5 | 4 | 4 |
Bayer AG (3.36) | 9 | 13 | 10 | 19 |
Roche Holding AG (3.23) | 10 | 9 | 6 | 10 |
Novo Nordisk A/S (2.97) | 11 | 10 | 8 | 11 |
Eisai Co. Ltd (2.95) | 12 | 11 | 14 | 16 |
Boehringer Ingelheim (2.93) | 13 | 12 | 16 | 12 |
Gilead Sciences (2.84) | 14 | 14 | 19 | 20 |
Bristol Myers Squibb (2.60) | 15 | 19 | 13 | 8 |
Astellas Pharma Inc (2.46) | 16 | 14 | 12 | 5 |
Daiichi Sankyo Co. Ltd (2.20) | 17 | 16 | 18 | 18 |
Merck & Co. Inc (2.15) | 18 | 15 | 17 | 9 |
AbbVie Inc (1.84) | 19 | 17 | 20 | 17 |
Eli Lilly & Co (1.79) | 20 | 18 | 15 | 13 |
The Access to Medicine Index was developed starting in 2004 on the initiative of Dutch entrepreneur Wim Leereveld. [7] After years of working with the pharmaceutical industry, he concluded that simply "naming and shaming" the industry did not do enough to encourage pharmaceutical companies to play their part in improving access to medicine in the developing world. Leereveld noticed that there were many different (and sometimes conflicting) opinions about what the pharmaceutical industry should be doing with regard to access to medicine, but that there was no tool to recognise good practice within the pharmaceutical industry and no framework for collective dialogue surrounding this issue. He set out to develop a ranking system that would show which pharmaceutical companies do the most to improve access to medicine and how, and also help stakeholders to collectively define companies' role in increasing access to medicine. [7]
The first Access to Medicine Index was published in 2008, followed by new Indexes in 2010, 2012, 2014, 2016, 2018, 2021 and 2022.
The methodology for the Access to Medicine Index is reviewed every two years, ahead of each analysis. The methodology for the 2024 Index, due for publication in November 2024, was published in October 2023. [8]
The Access to Medicine Index uses a weighted analysis to capture and compare data which the companies provide, as well as publicly available data. The framework is constructed along three areas of focus called "Technical Areas", which cover the range of company business activities considered relevant to access to medicine: Governance of Access, Research and Development, and Product Delivery. [8]
The methodology for the 2024 Index includes a greater focus on 'patient reach'. Jayasree K. Iyer, CEO of the Foundation, said this was settled on “after engaging with various stakeholders, from the World Health Organisation to patient organisations, NGOs, governments, and investors to arrive at a multi-stakeholder consensus.” [9]
Company scope
The Access to Medicine Index ranks 20 of the world's largest originator (research-based) pharmaceutical companies, based on market capitalisation and the relevance of their product portfolios to diseases in the developing world. One unlisted company, Boehringer Ingelheim, is also included since it meets the size and portfolio relevance criteria.
In 2008 and 2010, the first two editions of the Access to Medicine Index, companies engaged exclusively in the production of generic drugs were also assessed. [10] [11] Based on feedback from the 2011 stakeholder consultations, these companies were excluded from the 2012 Index and subsequent iterations. The Access to Medicine Foundation stated that it recognised that these companies play a significant role in access to medicine, particularly in low- and middle-income countries. [1] [12] [13] [14] [15] In 2023, the Access to Medicine Foundation launched a dedicated Generic & Biosimilar Medicines Programme, with its own analytical framework. [16] [17]
Geographic scope
The Access to Medicine Index focuses on low- and middle-income countries, based on World Bank and United Nations classifications measuring economic advancement, human development, and relative levels of inequality. [18] [19] The 2022 Index measured developments in a total of 108 countries, including countries considered to be low income and lower-middle income countries by the World Bank, and Least Developed Countries as defined by the United Nations Economic and Social Council. [20] In addition, countries classified as low human development countries and medium human development countries by the UN Human Development Index are included. Finally, based on the UN Inequality-Adjusted Human Development Index, the index includes countries which, while they may have higher measures of development, have comparatively high levels of socio-economic inequality. [1]
Disease scope
The Access to Medicine Index covers a range of diseases based on their aggregate global disease burden and their relevance to pharmaceutical interventions, in accordance with non-age-weighted WHO Disability Adjusted Life Years (DALY) [21] data. In the 2022 Index, the disease scope included 83 diseases, conditions and pathogens identified as the most critical priorities regarding access to medicine. [22]
Product type scope
To reflect the range of available product types for prevention, diagnosis and treatment of diseases, the Index maintains a broad product type scope which draws closely from definitions provided by the G-Finder Report. [23]
The Access to Medicine Index has become a frequently cited benchmark for pharmaceutical companies with regard to their access to medicine initiatives. In addition to global media outlets reporting on the Access to Medicine Index and its findings, significant coverage includes:
The results of the Access to Medicine Index are largely based on company data provided by the pharmaceutical companies themselves. Self-reported data does carry with it an inherent risk, but the Access to Medicine Index also uses dependable external sources to verify data provided by the companies wherever possible. Additionally, it is in companies' best interest to be as forthcoming as possible, as they are a) rated by the index on their degree of transparency and b) rated on their performance every two years, so that failures to meet their commitments and/or inconsistencies over time are likely to be uncovered. Besides, as drug access is only one dimension of the Corporate Social Responsibility (CSR) within the pharmaceutical industry, it would not be reasonable to evaluate the CSR practices of pharmaceutical companies only using this index.
A health system, health care system or healthcare system is an organization of people, institutions, and resources that delivers health care services to meet the health needs of target populations.
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849, in New York by two German entrepreneurs, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891).
An orphan drug is a pharmaceutical agent that is developed to treat certain rare medical conditions. An orphan drug would not be profitable to produce without government assistance, due to the small population of patients affected by the conditions. The conditions that orphan drugs are used to treat are referred to as orphan diseases. The assignment of orphan status to a disease and to drugs developed to treat it is a matter of public policy that depends on the legislation of the country.
The pharmaceutical industry is an industry involved in medicine that discovers, develops, produces, and markets pharmaceutical goods for use as drugs which are then administered to patients. These medications are created and put to market for the curing or preventing of disease, as well as alleviating symptoms of illness or injury.
The 10/90 gap is the term adopted by the Global Forum for Health Research to highlight the finding by the Commission on Health Research for Development in 1990, that less than 10% of worldwide resources devoted to health research were put towards health in Developing Countries, where over 90% of all preventable deaths worldwide occurred. Every year, the spread of disease suffered in both rich and poor countries converges. According to the World Health Organization (WHO), the most prevalent diseases consist of cardiovascular disease, cancer and diabetes. These diseases now account for 45% of the global health burden and are the culprit for up to 85% of deaths in low-income countries. The 10/90 Gap focuses on joining organizations together to reduce these statistics.
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.
Global health is the health of populations in a worldwide context; it has been defined as "the area of study, research, and practice that places a priority on improving health and achieving equity in health for all people worldwide". Problems that transcend national borders or have a global political and economic impact are often emphasized. Thus, global health is about worldwide health improvement, reduction of disparities, and protection against global threats that disregard national borders, including the most common causes of human death and years of life lost from a global perspective.
Essential medicines, as defined by the World Health Organization (WHO), are medicines that "satisfy the priority health care needs of the population". Essential medicines should be accessible to people at all times, in sufficient amounts, and be generally affordable. Since 1977, the WHO has published a model list of essential medicines, with the 2019 list for adult patients containing over 400 medicines. Since 2007, a separate list of medicines intended for child patients has been published. A new list was published in 2021, for both adults and children.
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
The Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients' needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases, notably leishmaniasis, sleeping sickness, Chagas disease, malaria, filarial diseases, mycetoma, paediatric HIV, cryptococcal meningitis, hepatitis C, and dengue. DNDi's malaria activities were transferred to Medicines for Malaria Venture (MMV) in 2015.
Neglected tropical diseases (NTDs) are a diverse group of tropical infections that are common in low-income populations in developing regions of Africa, Asia, and the Americas. They are caused by a variety of pathogens, such as viruses, bacteria, protozoa, and parasitic worms (helminths). These diseases are contrasted with the "big three" infectious diseases, which generally receive greater treatment and research funding. In sub-Saharan Africa, the effect of neglected tropical diseases as a group is comparable to that of malaria and tuberculosis. NTD co-infection can also make HIV/AIDS and tuberculosis more deadly.
mHealth is an abbreviation for mobile health, a term used for the practice of medicine and public health supported by mobile devices. The term is most commonly used in reference to using mobile communication devices, such as mobile phones, tablet computers and personal digital assistants (PDAs), and wearable devices such as smart watches, for health services, information, and data collection. The mHealth field has emerged as a sub-segment of eHealth, the use of information and communication technology (ICT), such as computers, mobile phones, communications satellite, patient monitors, etc., for health services and information. mHealth applications include the use of mobile devices in collecting community and clinical health data, delivery/sharing of healthcare information for practitioners, researchers and patients, real-time monitoring of patient vital signs, the direct provision of care as well as training and collaboration of health workers.
Medication costs, also known as drug costs are a common health care cost for many people and health care systems. Prescription costs are the costs to the end consumer. Medication costs are influenced by multiple factors such as patents, stakeholder influence, and marketing expenses. A number of countries including Canada, parts of Europe, and Brazil use external reference pricing as a means to compare drug prices and to determine a base price for a particular medication. Other countries use pharmacoeconomics, which looks at the cost/benefit of a product in terms of quality of life, alternative treatments, and cost reduction or avoidance in other parts of the health care system. Structures like the UK's National Institute for Health and Clinical Excellence and to a lesser extent Canada's Common Drug Review evaluate products in this way.
Omani nationals have free access to the country's public healthcare, though expatriates typically seek medical care in private sector clinics and hospitals. Generally, the standard of care in the public sector is high for a middle-income country. Oman now has very low rate of once common communicable diseases such as measles and typhoid. Due to rapidly increasing incomes and changing lifestyles and diet, the levels of non-communicable diseases such as cardiovascular disease and diabetes are an increasing problem.
Klaus M. Leisinger is a social scientist and economist. He is founder and president of the Global Values Alliance in Basel. Until 2012 he was managing director and chairman of the Board of Trustees of the Novartis Foundation in Basel, Switzerland.
Healthcare in the United States is largely provided by private sector healthcare facilities, and paid for by a combination of public programs, private insurance, and out-of-pocket payments. The U.S. is the only developed country without a system of universal healthcare, and a significant proportion of its population lacks health insurance. The United States spends more on healthcare than any other country, both in absolute terms and as a percentage of GDP; however, this expenditure does not necessarily translate into better overall health outcomes compared to other developed nations. Coverage varies widely across the population, with certain groups, such as the elderly and low-income individuals, receiving more comprehensive care through government programs such as Medicaid and Medicare.
Ceritinib is a prescription-only drug used for the treatment of non-small cell lung cancer (NSCLC). It was developed by Novartis and received FDA approval for use in April 2014.
Access to medicines refers to the reasonable ability for people to get needed medicines required to achieve health. Such access is deemed to be part of the right to health as supported by international law since 1946.
Health Action International (HAI) is a non-profit organization based in The Netherlands. Established in 1981, HAI works to expand access to essential medicines through research, policy analysis and intervention projects. The organization focuses on snakebite envenoming, access to insulin and developing European policies on medicines. HAI is listed by the World Health Organization (WHO) as an official non-state actor.
The Initiative for Medicines, Access, and Knowledge, known as I-MAK, is a U.S.-based global 501(c)(3) organization that advocates in the public interest for affordable access to medicines, and a medicines system that is more inclusive of patients and the public.
{{cite journal}}
: CS1 maint: multiple names: authors list (link){{cite journal}}
: CS1 maint: multiple names: authors list (link){{cite journal}}
: CS1 maint: DOI inactive as of December 2024 (link)